Unasyn 3 g Every Six Hours for Cellulitis
Unasyn (ampicillin-sulbactam) 3 g IV every 6 hours is an appropriate dosing regimen for cellulitis, with treatment duration of 5 days that should be extended if infection has not improved, and requires dose adjustment for creatinine clearance below 30 mL/min.
Dosing Regimen
The 3 g dose (2 g ampicillin + 1 g sulbactam) every 6 hours falls within the FDA-approved dosing range of 1.5-3 g every 6 hours for adults 1. This regimen should be administered as:
- Slow IV injection over 10-15 minutes, OR
- IV infusion in 50-100 mL compatible diluent over 15-30 minutes 1
The total sulbactam dose must not exceed 4 grams per day, which your regimen respects (4 g/day at 1 g every 6 hours) 1.
Treatment Duration
The recommended duration is 5 days, but extend treatment if the infection has not improved within this timeframe 2. This is a strong recommendation with high-quality evidence from IDSA guidelines. The FDA label notes that IV therapy should not routinely exceed 14 days 1.
Renal Dose Adjustment
Renal function critically impacts dosing because ampicillin and sulbactam elimination kinetics are similarly affected 1:
- CrCl ≥30 mL/min: 1.5-3 g every 6-8 hours (your regimen is appropriate)
- CrCl 15-29 mL/min: 1.5-3 g every 12 hours
- CrCl 5-14 mL/min: 1.5-3 g every 24 hours 1
For hemodialysis patients, doses should be given every 24 hours, administered after dialysis sessions since approximately 35% of ampicillin and 45% of sulbactam are removed during 4-hour hemodialysis 3.
Clinical Context for Cellulitis
This dosing is appropriate for moderate cellulitis with systemic signs of infection where coverage against both streptococci and MSSA is desired 2. The IDSA guidelines support this approach as a weak recommendation with low-quality evidence for including MSSA coverage in moderate nonpurulent SSTI.
Important Caveats:
- Mild cellulitis without systemic signs may only require streptococcal coverage, making Unasyn potentially broader than necessary 2
- Severe cellulitis with MRSA risk factors (penetrating trauma, purulent drainage, SIRS, injection drug use) requires vancomycin or another MRSA-active agent instead 2
- Severely compromised patients may need broader coverage (vancomycin plus piperacillin-tazobactam or a carbapenem) 2
Efficacy Evidence
Ampicillin-sulbactam demonstrates excellent efficacy for skin and soft tissue infections, with clinical cure or improvement rates of 80-100% in comparative trials 4, 5. The regimen is cost-effective compared to broader-spectrum alternatives 6.
Monitoring
Elevation of the affected area and treatment of predisposing factors (edema, interdigital toe space infections) should accompany antibiotic therapy 2. Reassess at 5 days to determine if treatment extension is needed based on clinical response.